Skip to Content
Merck
  • Rapid Elevation in CMPF May Act As a Tipping Point in Diabetes Development.

Rapid Elevation in CMPF May Act As a Tipping Point in Diabetes Development.

Cell reports (2016-03-22)
Ying Liu, Kacey J Prentice, Judith A Eversley, Cheng Hu, Battsetseg Batchuluun, Katherine Leavey, Jakob B Hansen, David W Wei, Brian Cox, Feihan F Dai, Weiping Jia, Michael B Wheeler
ABSTRACT

Prediabetes, a state of mild glucose intolerance, can persist for years before a sudden decline in beta cell function and rapid deterioration to overt diabetes. The mechanism underlying this tipping point of beta cell dysfunction remains unknown. Here, the furan fatty acid metabolite CMPF was evaluated in a prospective cohort. Those who developed overt diabetes had a significant increase in CMPF over time, whereas prediabetics maintained chronically elevated levels, even up to 5 years before diagnosis. To evaluate the effect of increasing CMPF on diabetes progression, we used obese, insulin-resistant models of prediabetes. CMPF accelerated diabetes development by inducing metabolic remodeling, resulting in preferential utilization of fatty acids over glucose. This was associated with diminished glucose-stimulated insulin secretion, increased ROS formation, and accumulation of proinsulin, all characteristics of human diabetes. Thus, an increase in CMPF may represent the tipping point in diabetes development by accelerating beta cell dysfunction.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Glucose-6-Phosphate Dehydrogenase Activity Assay Kit, sufficient for 100 colorimetric tests